Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
PLEASANTON, Calif., June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to simplify and streamline medical device and diagnostics studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from Veeva MedTech.
With a growing number of medical device and diagnostic clinical trials executed on Veeva Clinical applications, companies can gain the scalability to grow while maintaining compliance with local, regional, and global regulations. Medtechs of all sizes use Veeva to drive improvements, with customers achieving 50% faster study build times with Veeva EDC and 80% reductions in duplicate trial documents with Veeva eTMF.
"It's exciting to partner with the industry as it moves to Veeva MedTech for a complete and connected medical device and diagnostics clinical trials infrastructure," said Kevin Liang, vice president of clinical strategy at Veeva MedTech. "We're working with leading medtechs to advance study execution, collaboration, and innovation to bring life-changing products to patients faster."
What the medtech clinical industry is saying about Veeva:
"With Veeva EDC, we've partnered closely with their team to enhance the global library and develop reusable standards.," said Leianne Ebert, head of clinical data operations at Alcon. "We focused on getting standards right, and that commitment drove 50% standardization in one year, boosting our compliance with our global library."
"Veeva allows us to collect study data consistently in a manner that regulatory agencies will accept," said Kimberly Dorsch, vice president of global clinical affairs at LifeNet Health. "Whether it's a registry study or an IDE/IND study supporting a PMA/BLA, the data's going to be collected the exact same way and in a compliant manner."
"Since implementing Veeva eTMF, we've reduced our quality control time by over 90% and decreased our document creation times significantly," said Matt Christensen, senior vice president, global clinical and medical affairs at Smith+Nephew.
Learn more about Veeva Clinical Platform applications for medtech at veeva.com/MedTechClinical.
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:Deivis MercadoVeeva Systems925-226-8821deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtech-industry-establishes-foundation-for-clinical-trials-with-veeva-medtech-302477387.html
SOURCE Veeva Systems
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
5 High-Yield Stock Picks to Add to Your Dividend Portfolio
Key Points Verizon and Realty Income may not offer much growth, but their ability to fund growing dividend payments is rock-solid. Pfizer struggled following the wind-down of the coronavirus pandemic, with nothing offsetting declining sales of Paxlovid. That's changing. Exchange-traded funds are an easy diversification solution for at least a portion of your dividend portfolio. 10 stocks we like better than Pfizer › Does the prospect of economic uncertainty have you rethinking your portfolio? Perhaps you'd like to collect a little more cash while the economic headwinds are blowing? It's not an unreasonable concern. Plenty of other investors are already thinking more defensively than they've felt they needed to in a while. To this end, here's a closer look at five high-yielding dividend stocks to consider adding to your portfolio sooner rather than later, until it's clear the worst is behind us. 1. Verizon Communications Dividend yield: 6.2% Verizon Communications (NYSE: VZ) is, of course, one of the country's biggest wireless service providers, boasting well over 100 million paying customers who collectively handed over nearly $135 billion worth of revenue last year alone. Of that, $18 billion was turned into net income, $11.25 billion of which was dished out to shareholders in the form of dividends. That's in line with the company's long-term norms. There is an arguable downside here. That's growth ... or lack thereof. The well-saturated U.S. wireless market doesn't offer much in the way of upside potential above and beyond simple population growth. Verizon is finding some inroads within the institutional/private 5G communications space, but that's a highly competitive market. There's just not a ton of expansion to be added here either. What Verizon may lack in growth potential, however, it more than makes up for in consistency and sheer payout. Nobody's interested in giving up their mobile phones, which supports a sizable forward-looking yield of 6.2% that's based on a dividend that has now been raised for 18 consecutive years. Not bad. 2. Realty Income Dividend yield: 5.6% Realty Income (NYSE: O) isn't a stock in the traditional sense. Rather, it's a real estate investment trust, or REIT. That just means it owns a portfolio of rent-bearing real estate. REITs trade just like ordinary stocks do, and pay dividends the same way that dividend stocks do, too. And Realty Income brings something else to the table that's pretty unique in addition to its sizable forward-looking yield of 5.6%. That's a monthly dividend payment, as opposed to the quarterly cadence you'll get with most other dividend stocks. Realty Income's specialty is retailing real estate. In light of the so-called "retail apocalypse" that seems to never end, this focus seems like a liability. Just take a step back and look at the bigger picture. While numbers from Coresight Research point out that 7,325 U.S. stores were shuttered last year, 5,970 new stores were opened (or reopened). Realty Income further narrows this gap by serving the strongest survivors in the business. Its top tenants include 7-Eleven, Dollar General, Dollar Tree, and FedEx, just to name a few. Underscoring the quality caliber of its renters is the fact that its occupancy rate currently stands at an industry-beating 98.5%, and only fell to 97.9% in COVID-crimped 2020. This resilience is one of the reasons the REIT has been able to raise its payout annually for the past 30 consecutive years. 3. SPDR Portfolio S&P 500 High Dividend ETF Dividend yield: 4.6% Speaking of dividend stocks that aren't actually stocks, add the SPDR Portfolio S&P 500 High Dividend ETF (NYSEMKT: SPYD) to your watch list, if not to your portfolio. An ETF (or exchange-traded fund) is a basket of stocks with a common characteristic. In this instance, these tickers are all part of the S&P 500 High Dividend Index, which tracks the 80 highest-yielding names within the S&P 500. These include Philip Morris, toymaker Hasbro, AT&T, and Ford Motor Company, for reference. None of these names has a great deal of growth firepower. All of them, however, are healthy dividend payers. Most of them also have a solid track record of dividend growth, even if it's not required for inclusion in the underlying index. Sure, you can probably find higher dividend yields than the one SPYD offers. The aforementioned Realty Income and Verizon both boast bigger ones, for instance. The SPDR Portfolio S&P 500 High Dividend ETF is still an incredibly simple way of achieving a well-diversified mix of dividend stocks though, with a little more potential for capital appreciation than Verizon or Realty Income offer. 4. Pfizer Dividend yield: 6.9% It's no secret that drugmaker Pfizer (NYSE: PFE) has underperformed since the wind-down of COVID-19, which upended sales of its Paxlovid approved to treat the disease. The company's top line has slipped from 2022's $100 billion to only $64 billion last year, for perspective, and analysts aren't looking for any sales growth this year or next either. That's the chief reason Pfizer shares continue to flounder. If you can look just a little further down the road though, some new blockbuster drugs are in the works -- drugs like vepdegestrant, for the treatment of ER+/HER2- metastatic breast cancer. While it will be competing with plenty of other therapies in this same space, it's noteworthy that the FDA fast-tracked this drug, which is being co-developed with Arvinas. And that's just one. Pfizer got a total of four promising oncology drugs with its 2023 acquisition of Seagen, and now has over 100 clinical trials underway, 30 of which are in phase 3 (late-stage) testing. Indeed, the company believes it's got eight oncology candidates in its developmental pipeline that could become blockbusters by 2030. Little of this long-term upside is being reflected in the stock's present price, however, even though it arguably should be. More to the point for interested income investors, this pharmaceutical stock's weakness has pushed its forward-looking dividend yield up to nearly 7% at a point where the pharma giant is on the verge of significant prolonged revenue and profit growth. 5. Global X Nasdaq 100 Covered Call ETF Dividend yield: 14% Finally, consider adding a stake in the Global X Nasdaq 100 Covered Call ETF (NASDAQ: QYLD) to your dividend portfolio. It's not a stock. It's an exchange-traded fund. And an unusual one at that. While it holds the same tickers that make up the tech-heavy Nasdaq-100 index, serving as an index fund isn't its primary purpose. Rather, this ETF's purpose is to generate reliable income that's regularly distributed to shareholders by selling covered calls against the ETF's stock holdings. It's an income-generating process called "buy-write," in fact -- you're buying a stock, and then "writing" (or selling) call options on those shares, essentially using them as collateral. And the process works. Although the income generated by writing covered calls over and over again can be erratic (don't count on that trailing 14% yield going forward), the resulting reliable yields are typically big even if they're not precisely predictable. There's also a big downside, though. That is, this fund is almost certainly guaranteed to underperform the Nasdaq-100 itself, even after factoring in all of its sizable dividend payments. That's just the nature of selling covered calls -- the strategy doesn't let you fully participate when the market's rallying the most. Writing options is just a means of monetizing stock holdings when they're mostly moving sideways, or losing ground. Still, with a double-digit yield, even only capturing a portion of the Nasdaq-100's long-term upside isn't a bad bet. It's just arguably not the only dividend-paying investment you'd want to own at any given time, mostly due to its inconsistent payments. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 James Brumley has positions in AT&T. The Motley Fool has positions in and recommends FedEx, Pfizer, and Realty Income. The Motley Fool recommends Hasbro, Philip Morris International, and Verizon Communications. The Motley Fool has a disclosure policy. 5 High-Yield Stock Picks to Add to Your Dividend Portfolio was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
RLI (RLI) Q2 Earnings Report Preview: What To Look For
Specialty insurance provider RLI (NYSE:RLI) will be reporting earnings this Monday afternoon. Here's what you need to know. RLI missed analysts' revenue expectations by 7.8% last quarter, reporting revenues of $407.7 million, down 8.4% year on year. It was a softer quarter for the company, with a significant miss of analysts' book value per share estimates and a slight miss of analysts' net premiums earned estimates. Is RLI a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting RLI's revenue to grow 7.5% year on year to $447.6 million, slowing from the 9.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.78 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. RLI has missed Wall Street's revenue estimates four times over the last two years. Looking at RLI's peers in the insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Progressive delivered year-on-year revenue growth of 21.3%, beating analysts' expectations by 1.4%, and Travelers reported revenues up 7.4%, in line with consensus estimates. Progressive traded up 2.2% following the results while Travelers was also up 5.5%. Read our full analysis of Progressive's results here and Travelers's results here. Investors in the insurance segment have had fairly steady hands going into earnings, with share prices down 1.7% on average over the last month. RLI is down 2.7% during the same time and is heading into earnings with an average analyst price target of $74.67 (compared to the current share price of $70.25). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
2 hours ago
- Yahoo
ICICI Bank Ltd (IBN) Q1 2026 Earnings Call Highlights: Strong Profit Growth Amid Asset Quality ...
Release Date: July 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points ICICI Bank Ltd (NYSE:IBN) reported a 15.5% year-on-year increase in profit after tax, reaching ?127.68 billion for the quarter. The bank's core operating profit increased by 13.6% year-on-year to ?175.05 billion. Total deposits grew by 12.8% year-on-year, with average deposits increasing by 11.2% year-on-year and 3.1% sequentially. The business banking portfolio showed strong growth, increasing by 29.7% year-on-year and 3.7% sequentially. ICICI Bank Ltd (NYSE:IBN) maintained a strong capital position with a CET1 ratio of 16.31% and a total capital adequacy ratio of 16.97%. Negative Points The rural loan portfolio declined by 0.4% year-on-year and 1.5% sequentially. The retail loan portfolio growth was modest, increasing by only 6.9% year-on-year and 0.5% sequentially. The net interest margin decreased to 4.34% from 4.41% in the previous quarter. There were net additions of ?30.34 billion to gross NPAs, indicating ongoing challenges in asset quality. The overseas loan portfolio remained small, constituting only 2.4% of the overall loan book. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with IBN. Q: Can you provide a like-to-like comparison of margins for the fourth quarter, considering the change in method and the impact of the tax refund? A: The reported margin for Q4 would have been a few basis points lower, and the range you mentioned is probably correct. However, the same spike will not occur in the current year, and we expect a more even spread of the reported margin throughout the year. (Unidentified_3) Q: With the current credit cost, do you expect further normalization, or is this the clean credit cost we should expect going forward? A: The underlying level is currently around 50 basis points, and we don't foresee any major movement. The current credit cost is reflective of the underlying conditions. (Unidentified_3) Q: Regarding the business banking segment, what factors contributed to the strong performance, and how do you see the mix of credit growth evolving over the next few years? A: The success in business banking is due to a combination of distribution, process, technology, and digital capabilities. We expect business banking fees to grow faster than the overall loan book, gradually increasing its proportion. (Unidentified_3) Q: How do you see the behavior of CASA deposits changing with rate cuts, and do you expect market share to stabilize or grow? A: We don't see a significant change in the competitive scenario. We will continue to focus on increasing customer acquisition and becoming the primary banker, which should help us maintain or grow our market share. (Unidentified_3) Q: How are you approaching unsecured retail growth, given the systemic softness in credit demand? A: We are comfortable with the quality of origination in personal loans and credit cards over the last 12-15 months. We expect to see better growth and customer acquisition in these segments going forward. (Unidentified_3) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
